| Theme | Best Available Managements of Helicobacter pylori Gastritis | |
|---|---|---|
| Title | Therapy for Helicobacter pylori Infection Eradication | |
| Publish Date | 2014/03 | |
| Author | Tomoyuki Yada | Department of Gastroenterology, Kohnodai Hospital, National Center for Global Health and Medicine |
| Author | Naomi Uemura | Department of Gastroenterology, Kohnodai Hospital, National Center for Global Health and Medicine |
| Author | Daizo Saito | Nihonbashi Daizo Clinic |
| [ Summary ] | Since February 2013, all Helicobacter pylori (H. pylori) infections have been covered by the National Health Insurance system in Japan. Two types of treatment programs covered through insurance are first-line eradication therapy (PPI/AC) consisting of proton pump inhibitors (PPI), amoxicillin, and clarithromycin (CAM), and secondline eradication therapy (PPI/AM) consisting of these same drugs but with metronidazole instead of CAM. Regimens have been determined for each therapy. There are six methods for evaluating the results of eradication therapy. The urea breath test or the stool antigen test are the most commonly recommended methods. These posteradication assessments are conducted at least four weeks after treatment completion. To provide appropriate medical care, it is essential for all physicians involved in the treatment for H. pylori infection to be proficient in diagnosis, eradication therapy, posteradication assessment of infection, and followups. | |